Fundraising FoxRevBio (formerly LaunchPad Medical)
Lowell, US · Founded 2016 · 3 known investors
Find your way into RevBio (formerly LaunchPad Medical)
Sign up to see every warm intro you have to RevBio (formerly LaunchPad Medical)
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RevBio (formerly LaunchPad Medical) team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
RevBio develops a biomimetic bone adhesive platform derived from marine biology for bone repair and regenerative applications across dental, orthopedic, and neurosurgical indications. The company is conducting first-in-human clinical trials on its regenerative bone glue technology.
Founders & leadership
RevBio (formerly LaunchPad Medical) was founded in 2016 by Brian Hess.
BH
Brian HessChief Executive Officer, FounderBrian Hess is Chief Executive Officer and Founder of RevBio, a clinical-stage medical device company developing a bone adhesive platform for orthopedic, dental, and neurosurgical applications.
DG
D. GRAYSON ALLENExecutiveD. Grayson Allen is an executive officer and director at Revbio with over 20 years of experience in finance roles across startups and growth-stage companies, including capital structuring, financial analysis, and team leadership.
Board
KF
KEVIN FOLEYBoard director
GK
GEORGE KAYBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$32.5M disclosed across 3 rounds · 2018–2023
▶$15MraisedOct 2026 · 72 investors · Other Health CareRule 506(b)
▶$15MraisedOct 2026 · 72 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- BRIAN HESSExecutive Officer, Director
- GEORGE KAYDirector
- D. GRAYSON ALLENExecutive Officer, Director
- KEVIN FOLEYDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9MraisedMay 2022 · 34 investors · Other Health CareRule 506(b)
▶$9MraisedMay 2022 · 34 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- D. GRAYSON ALLENExecutive Officer, Director
- KEVIN FOLEYDirector
- GEORGE KAYDirector
- BRIAN HESSExecutive Officer, Director
- Offering amount
- $10.2M
- Amount sold
- $9M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedJan 2019 · 71 investors · Other Health CareRule 506(b)
▶$8.5MraisedJan 2019 · 71 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- BRIAN HESSExecutive Officer
- GEORGE KAYDirector
- D. GRAYSON ALLENExecutive Officer, Director
- Offering amount
- $9.5M
- Amount sold
- $8.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $375K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $197.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does RevBio (formerly LaunchPad Medical) do?
- RevBio develops a biomimetic bone adhesive platform derived from marine biology for bone repair and regenerative applications across dental, orthopedic, and neurosurgical indications. The company is conducting first-in-human clinical trials on its regenerative bone glue technology.
- Who founded RevBio (formerly LaunchPad Medical)?
- RevBio (formerly LaunchPad Medical) was founded by Brian Hess in 2016.
- Who are RevBio (formerly LaunchPad Medical)'s investors?
- RevBio (formerly LaunchPad Medical)'s investors include Arieal Southeast Angel Partners, Beacon Angels, Boston Harbor Angels.
- How much funding has RevBio (formerly LaunchPad Medical) raised?
- RevBio (formerly LaunchPad Medical) has disclosed $32.5M raised across 3 rounds.
- Where is RevBio (formerly LaunchPad Medical) headquartered?
- RevBio (formerly LaunchPad Medical) is headquartered in Lowell, US.